Vollständiger Abstract
Worum geht es in dieser Arbeit?
Abstract Background Renin-angiotensin system (RAS) inhibitors are a cornerstone of cardiovascular and kidney risk modification in chronic kidney disease (CKD). Yet, they are often discontinued in advanced CKD to limit adverse effects or to delay kidney replacement therapy (KRT). Methods From the CKD-Renal Epidemiology and Information Network prospective cohort study, we selected participants with an estimated glomerular filtration rate (eGFR)
Bibliografischer Nachweis
Publikationsdaten
- Autor:innen
- Valentin Maisons, Margaux Costes-Albrespic, Sophie Liabeuf, Solène M Laville, Ziad Massy, Angelo Karaboyas, Roberto Pecoits-Filho, Emilie Moutard, Marie Metzger, Jean-Michel Halimi, Etienne Dantan, Natalia Alencar de Pinho, Bénédicte Sautenet
- Quelle
- Clinical Kidney Journal
- Publikation
- 2026-01-01
- Band / Ausgabe
- Nicht angegeben
- Seiten
- Nicht angegeben
- ISSN / ISBN
- 2048-8505, 2048-8513
- Zitationen
- 0 laut Crossref
- Referenzen
- 0 hinterlegt
Zitieren
Zitierfähiger Nachweis
Valentin Maisons, Margaux Costes-Albrespic, Sophie Liabeuf, Solène M Laville, Ziad Massy, Angelo Karaboyas, Roberto Pecoits-Filho, Emilie Moutard, Marie Metzger, Jean-Michel Halimi, Etienne Dantan, Natalia Alencar de Pinho, Bénédicte Sautenet (2026). Impact of renin-angiotensin system inhibitors discontinuation in advanced chronic kidney disease: a target trial emulation. Clinical Kidney Journal. https://doi.org/10.1093/ckj/sfag304
Kontext
Themen, Förderung und Nutzung
Lizenzhinweise: Lizenz 1